Trial Profile
POSITION: A Pilot Study of Induction PARP Inhibition in Ovarian Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Feb 2022
Price :
$35
*
At a glance
- Drugs Talazoparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms POSITION
- 11 Feb 2022 Status changed from active, no longer recruiting to completed.
- 03 Feb 2022 Planned End Date changed from 1 Feb 2021 to 30 Jun 2022.
- 03 Feb 2022 Planned primary completion date changed from 1 Feb 2021 to 30 Jun 2022.